title: Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland.
abstract: BACKGROUND
  Guidelines for the management of anaemia in patients with chronic kidney disease (CKD) recommend a minimal haemoglobin (Hb) target of 11 g/dL. Recent surveys indicate that this requirement is not met in many patients in Europe. In most studies, Hb is only assessed over a short-term period. The aim of this study was to examine the control of anaemia over a continuous long-term period in Switzerland.
  
  
  METHODS
  A prospective multi-centre observational study was conducted in dialysed patients treated with recombinant human epoetin (EPO) beta, over a one-year follow-up period, with monthly assessments of anaemia parameters.
  
  
  RESULTS
  Three hundred and fifty patients from 27 centres, representing 14% of the dialysis population in Switzerland, were included. Mean Hb was 11.9 +/- 1.0 g/dL, and remained stable over time. Eighty-five % of the patients achieved mean Hb >or= 11 g/dL. Mean EPO dose was 155 +/- 118 IU/kg/week, being delivered mostly by subcutaneous route (64-71%). Mean serum ferritin and transferrin saturation were 435 +/- 253 microg/L and 30 +/- 11%, respectively. At month 12, adequate iron stores were found in 72.5% of patients, whereas absolute and functional iron deficiencies were observed in only 5.1% and 17.8%, respectively. Multivariate analysis showed that diabetes unexpectedly influenced Hb towards higher levels (12.1 +/- 0.9 g/dL; p = 0.02). One year survival was significantly higher in patients with Hb >or= 11 g/dL than in those with Hb <11 g/dL (19.7% vs 7.3%, p = 0.006).
  
  
  CONCLUSIONS
  In comparison to European studies of reference, this survey shows a remarkable and continuous control of anaemia in Swiss dialysis centres. These results were reached through moderately high EPO doses, mostly given subcutaneously, and careful iron therapy management.
authors.affiliation: Department of Nephrology, University Hospital CHUV, Lausanne, Switzerland. clm.mathieu@wanadoo.fr
authors.forename: Claudine M
authors.initials: CM
authors.lastname: Mathieu
authors.forename: Daniel
authors.initials: D
authors.lastname: Teta
authors.forename: Nathalie
authors.initials: N
authors.lastname: Lötscher
authors.forename: Dela
authors.initials: D
authors.lastname: Golshayan
authors.forename: Luca
authors.initials: L
authors.lastname: Gabutti
authors.forename: Denes
authors.initials: D
authors.lastname: Kiss
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Martin
authors.forename: Michel
authors.initials: M
authors.lastname: Burnier
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000517:prevention & control*; D015331:Cohort Studies; D015897:Comorbidity; D005260:Female; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000534:rehabilitation*; D008297:Male; D008875:Middle Aged; D011785:Quality Assurance, Health Care / Q000379:methods*; D006435:Renal Dialysis / Q000379:methods* / Q000706:statistics & numerical data*; D013557:Switzerland / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult